Llwytho...
The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in non‐small‐cell lung cancer (NSCLC), but our understanding of biomarkers that predict the response to ICB remain obscure. Here we integrated somatic mutational profile and clinicopathologic information from 113 NSCLC...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer Sci |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6676111/ https://ncbi.nlm.nih.gov/pubmed/31222843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14113 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|